Biological Profile and Cardiovascular Risk in Patients Receiving Neuroleptics at the Psychiatric Department of the University Hospital Center of Brazzaville
Several studies report the problem of cardiovascular tolerance of treatments with neuroleptics, given the important number of morbidities in patients with mental illnesses. This preliminary work aimed to describe the epidemiological and biological profile of patients taking neuroleptics and followed in the psychiatry department of Brazzaville University Hospital, from the angle of cardiovascular risk. Fifty (50) patients (17 men and 33 women), with a mean age of 33.9 ± 10.7 years, were included. Epidemiological data (sex, age, tobacco or alcohol consumption) were collected on pre-established survey forms. Biochemical (total cholesterol, HDL-c, triglycerides and atherogenicity index) and inflammatory parameters (ultra-sensitive CRP, troponin I and NT-ProBNP) were investigated using enzymatic and indirect immunofluorescence technical, respectively. The results obtained showed that 54% of patients were obese, 94% were non-smokers, and 12% had high blood pressure. 10% of patients had high total cholesterol levels and 90% had HDL cholesterol levels below 60 mg/dl. Triglycerides and atherogenicity index were significantly elevated in relation to Body Mass Index (BMI). Ultrasensitive CRP was elevated in 38% of patients. In conclusion, this study revealed an association between lipid parameters (triglycerides and atherogenicity index) in relation to BMI in patients taking neuroleptics followed in the Psychiatry Department of University Hospital Center of Brazzaville.
References
[1]
Monteil, C. (2019) Les comorbidités cardiaques associées aux neuroleptiques et le rôle du pharmacien dans l’accompagnement des patients. Thèse, Université de Picardie Jules Verne, Amiens. https://dumas.ccsd.cnrs.fr/dumas-03274524
[2]
Nasrallah, A.H. and Mulvihill, T. (2001) Iatrogenic Disorders Associated with Conventional vs. Atypical Antipsychotics. Annals of Clinical Psychiatry, 13, 215-227. https://doi.org/10.3109/10401230109147385
[3]
Casadebaig, F. and Philippe, A. (1999) Mortality in Schizophrenic Patients. 3 Years Follow-Up of a Cohort. L’Encéphale, 25, 329-337.
[4]
Newman, S.C. and Bland, R.C. (1991) Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study. The Canadian Journal of Psychiatry, 36, 239-245. https://doi.org/10.1177/070674379103600401
[5]
Gury, C., Canceil, O. and Iaria, P. (2000) Antipsychotics and Cardiovascular Safety: Current Data on QT Interval Prolongation and Risk of Ventricular Arrhythmias. Brain, 26, 62-72.
[6]
Haddad, P.M. and Anderson, I.M. (2002) Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs, 62, 1649-1671. https://doi.org/10.2165/00003495-200262110-00006
[7]
American Diabetes Association (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27, 596-601. https://doi.org/10.2337/diacare.27.2.596
[8]
Meyer, J.M. and Koro, C.E. (2004) The Effects of Antipsychotic Therapy on Serum Lipids: A Comprehensive Review. Schizophrenia Research, 70, 1-17. https://doi.org/10.1016/j.schres.2004.01.014
[9]
Chagraoui, A., Thibaut, F., Skiba, M., Thuillez, C. and Bourin, M. (2016) 5-HT2C Receptors in Psychiatric Disorders: A Review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 66, 120-135. https://doi.org/10.1016/j.pnpbp.2015.12.006
[10]
Boston, P., Dursun, S.M. and Reveley, M.A. (1996) Cholesterol and Mental Disorder. The British Journal of Psychiatry, 169, 682-689. https://doi.org/10.1192/bjp.169.6.682
[11]
Mabrouk, H., Mechria, H., Hellara, I., Ben Omrane, C., Neffati, F., Mechri, A., Douki, W., Gaha, L. and Najjar, M.F. (2012) Lipid Profile and Cardiovascular Risk in 121 Schizophrenia Patients. Immuno-analyse & Biologie Spécialisée, 27, 159-167. https://doi.org/10.1016/j.immbio.2012.04.002
[12]
Bait, S. (2023) Schizophrénie et Diabète: Caractérisation épidémiologique et clinique. Etude réalisée au service de psychiatrie de Ourgla durant la période allant du 01 Février 2019 au 31 Janvier 2020. Thèse d’exercice. Université de Constantin 3, Constantine.
[13]
Coodin, S. (2001) Body Mass Index in Persons with Schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie,46, 549-555. https://doi.org/10.1177/070674370104600610
[14]
Vancampfort, D., Wampers, M., Mitchell, A.J., et al. (2013) A Meta-Analysis of Cardio-Metabolic Abnormalities in Drug Naïve, First-Episode and Multi-Episode Patients with Schizophrenia versus General Population Controls. World Psychiatry,12, 240-250. https://doi.org/10.1002/wps.20069
[15]
Abidi, O., Vercherai, P., Massoubre, C. and Bois, C. (2018) Le risque cardiovasculaire global des patients atteints de schizophrénie hospitalisés en psychiatrie au CHU de Saint-Étienne. L’Encéphale, 45, 200-206. https://doi.org/10.1016/j.encep.2018.06.008
[16]
Rachida Belalta, R.B. (2022) Prévalence du syndrome métabolique chez les schizophrènes algériens. Algerian Journal of Medical and Health Research, 1, 4-13.
[17]
Lefebvre, N., Chéreau, I., Schmitt, A. and Llorca, P.M. (2006) Somatic Comorbidities in Patients with Treated Schizophrenia. Annales Médico-Psychologiques,164, 159-164. https://doi.org/10.1016/j.amp.2005.11.006
[18]
Joseph, K. (2022) Etude du syndrome métabolique chez les patients suivis dans le service de Psychiatrie du CHU Point G. University Of Science Of Technical And Technology De Bamako, Bamako.
[19]
Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. and Cook, N.R. (2002) Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. The New England Journal of Medicine, 347, 1557-1565. https://doi.org/10.1056/NEJMoa021993
[20]
Sakai, Y., Larsen, J.B. and Reitan, S.K. (2022) High-Sensitivity C-Reactive Protein Is Related to Age and Gender in an Acute Psychiatric Inpatient Population. Heliyon, 8, e08992. https://doi.org/10.1016/j.heliyon.2022.e08992
[21]
Fernandes, B.S., Steiner, J., Bernstein, H.-G., Dodd, S., Pasco, J.A., Dean, O.M., Nardin, P., Goncalves, C.A. and Berk, M. (2015) C-Reactive Protein Is Increased in Schizophrenia but Is not Altered by Antipsychotics: Meta-Analysis and Implications. Molecular Psychiatry, 21, 554-564. https://doi.org/10.1038/mp.2015.87
[22]
Wysokiński, A., Margulska, A., Strzelecki, D. and Kłoszewska, I. (2014) Levels of C-Reactive Protein (CRP) in Patients with Schizophrenia, Unipolar Depression and Bipolar Disorder. Nordic Journal of Psychiatry, 69, 346-353. https://doi.org/10.3109/08039488.2014.984755
[23]
Ezzaher, A., Haj Mouhamed, D., Mechri, A., Neffati, F., Douki, W., Gaha, L., et al. (2010) Obésité et dyslipidémie chez des patients bipolaires tunisiens. Annales de Biologie Clinique, 68, 277-284. https://doi.org/10.1684/abc.2010.0403
